Burosumab Treatment for Autosomal Recessive Hypophosphatemic Rickets Type 1 (ARHR1).
Xiuying BaiMark LeventalAndrew C KaraplisPublished in: The Journal of clinical endocrinology and metabolism (2022)
The present report highlights the beneficial biochemical and clinical outcomes associated with the use of burosumab in patients with ARHR1.